4D Molecular Therapeutics Announces $250M Proposed Public Offering Of Common Stock
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced a proposed public offering of $250 million of its common stock, with an option for underwriters to purchase an additional $37.5 million. The offering, managed by Goldman Sachs, BofA Securities, Jefferies, and Barclays, is subject to market conditions.
February 05, 2024 | 9:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
4D Molecular Therapeutics announces a $250M public offering of common stock, potentially expanding to $287.5M, managed by major financial institutions.
Public offerings often lead to short-term price declines due to the dilution of existing shares. Given the size of the offering relative to the company, this is likely to have a significant impact. The involvement of major financial institutions as managers might mitigate the impact slightly, but the primary effect is still expected to be negative in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100